SecBot SecBot
8-K ·Filed Jul 31, 2026

ABBV

AbbVie Inc.
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0001551152-26-000023
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The strong operational beat and robust growth in Skyrizi/Rinvoq support the core thesis, but the Apogee acquisition introduces near-term dilution and integration risk. Monitor the Q3 close of the Apogee deal and any pipeline readouts for zumilokibart (APG777) that could validate the $10.9B price tag.

DirectionBullish
Confidencehigh
Horizonweeks

Drugs in focus

ABBV drug pipeline →

Venclexta

● Neutral Named in this 8-K
Impact
Phase
Approved (marketed); supplemental/expansion trials Phase 3
Time to market
Already on the market — accelerated US approval 2016 (17p-deleted CLL), broader CLL/SLL approval 2019, AML approvals since 2018-2020, and newest first-line CLL combo approval February 2026.
Next catalyst
None dated

What to watchThe defining approvals are already in: Venclexta is a marketed CLL/AML franchise with a fresh US label expansion (first-line CLL combo, Feb 2026), so there is no pending PDUFA-style binary to trade, the next meaningful moves will come from quarterly hematology revenue commentary and competitive data from next-generation BCL-2 inhibitors (e.g., BeiGene's sonrotoclax). ABBV's stock is driven far more by its immunology portfolio (Skyrizi/Rinvoq) than by Venclexta, so position sizing should treat this drug as steady cash flow, not a swing factor.

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$250.94
T+0 close · Jul 31, 2026 · via day close
Latest settled
+14.27%
T+60 · $286.74
Vs SPY
+11.81%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 31 $250.94entry
  2. T+1 · 4mo ago −2.33%α −3.75% · $245.10
  3. T+5 · 3mo ago −1.95%α −5.46% · $246.04
  4. T+20 · 3mo ago +1.81%α −1.18% · $255.48
  5. T+60 · 22d ago +14.27%α +11.81% · $286.74
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

AbbVie reported Q2 2026 adjusted EPS of $3.65, a 1.2% beat vs. consensus of $3.61, on revenue of $16.99B (above $16.76B consensus, +10.2% YoY). The company announced a definitive agreement to acquire Apogee Therapeutics for ~$10.9B and slightly lowered its full-year adjusted EPS guidance to $13.87-$14.07 to reflect the deal's $0.14 dilutive impact, partially offset by $0.10 of operational overperformance. Strong growth in immunology (Skyrizi +24.4%, Rinvoq +24.5%) and neuroscience (+20.3%) continues to offset Humira erosion (-35.9%).

Key Financial Metrics

EPS
$3.65
est $3.61 · +1.1%
Revenue
$17.0B
est $16.8B · +1.4% · +10.2% YoY
Rating
beat
Gross Margin
74.7%

Key Facts

  • Q2 2026 adjusted EPS $3.65 vs. consensus $3.61 (+1.2% beat)
  • Q2 2026 revenue $16.99B vs. consensus $16.76B (+10.2% YoY reported)
  • Announced definitive agreement to acquire Apogee Therapeutics for ~$10.9B equity value
  • Full-year 2026 adjusted EPS guidance narrowed to $13.87-$14.07 from $13.91-$14.11 (includes $0.14 Apogee dilution)
  • Skyrizi revenue $5.505B (+24.4% YoY); Rinvoq $2.525B (+24.5% YoY); Humira $756M (-35.9% YoY)
  • Neuroscience revenue $3.228B (+20.3% YoY); Aesthetics $1.282B (+0.3% YoY)
  • Adjusted operating margin expanded to 48.3% from 46.7% in Q2 2025

Financial Impact

Adjusted EPS beat by $0.04 (+1.2%) vs consensus; revenue beat by ~$230M (+1.4%) vs consensus; $10.9B acquisition announced

revenueepsguidancedilution

Risk Factors

  • Apogee acquisition integration risk and $0.14 EPS dilution in 2026
  • Continued Humira erosion (-35.9% YoY) and potential biosimilar competition
  • Oncology portfolio decline (-1.5% YoY) and Imbruvica erosion (-29.4%)
  • Aesthetics portfolio stagnation (+0.3% YoY) with Juvederm decline (-6.0%)

Market Snapshot

Price
$251.80
Volume
362
Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
79% bullish (39 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001551152-26-000023
Document: abbv-20260731.htm0001551152-26-000023
Document: 0001551152-26-000023-index-headers.html0001551152-26-000023
Document: 0001551152-26-000023-index.html0001551152-26-000023
Document: 0001551152-26-000023.txt0001551152-26-000023
8-K Data (Synthetic)0001551152-26-000023

Track record

22 reports on ABBV

Performance horizon

6 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +27.21% at T+60 after the Apr 29, 2026 report. 6 of 8 went positive at some point.

Filters
  1. Nov 9, 20267d ago 144 Neutral 2/10 Entry $293.89 Now $294.55 +0.22% settles Dec 9
  2. Nov 2, 202614d ago 8-K Neutral 2/10 Entry $286.00 Now $294.55 +2.99% settles Dec 2
  3. Oct 30, 202617d ago 8-K Bullish 6/10 Entry $294.89 Now $294.55 −0.12% settles Nov 30
  4. Oct 29, 202619d ago Court Ruling Bullish 7/10 Entry $294.89 Now $294.55 −0.12% settles Nov 30
  5. Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $282.68 to $294.55 Now $294.55 +4.20% ▲ +4.20% +7.66% vs SPY
  6. Oct 15, 20264w ago 8-K Neutral 2/10 Entry $285.42 to $295.03 Now $294.55 +3.20% ▲ +3.37% +4.53% vs SPY
  7. Oct 5, 20266w ago 8-K Neutral 4/10 Entry $265.06 to $289.60 Now $294.55 +11.12% ▲ +9.26% +12.16% vs SPY
  8. Sep 28, 20267w ago Court Ruling Neutral 2/10 Entry $263.29 to $286.39 Now $294.55 +11.87% ▲ +8.77% +8.06% vs SPY
  9. Sep 14, 20269w ago Court Ruling Neutral Not scored Entry $261.43 to $272.69 Now $294.55 +12.67% ▲ +4.30% +1.33% vs SPY
  10. Sep 3, 202610w ago 8-K Neutral 4/10 Entry $260.21 to $262.82 Now $294.55 +13.20% ▲ +1.00% +2.19% vs SPY
Showing 10 of 22

US Market Status

Market Closed · Opens Wed (11h 3m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 31, 2026